利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.021 秒)

    Delivery of a sympatholytic cardiovascular agent to the central nervous system
    1.
    发明申请
    Delivery of a sympatholytic cardiovascular agent to the central nervous system 有权
    交配性心血管药物向中枢神经系统递送

    公开(公告)号：US20050177097A1

    公开(公告)日：2005-08-11

    申请号：US10903599

    申请日：2004-07-30

    申请人： Keith Hildebrand ,  Michael Ujhelyi ,  Xiaohong Zhou ,  Daniel Sigg ,  Linda Page

    发明人： Keith Hildebrand ,  Michael Ujhelyi ,  Xiaohong Zhou ,  Daniel Sigg ,  Linda Page

    IPC分类号： A61B5/02 ,  A61M5/142 ,  A61M5/168 ,  A61M5/172 ,  A61N1/39 ,  A61K31/137 ,  A61K9/22 ,  A61K31/24

    CPC分类号： A61M5/142 ,  A61M5/14276 ,  A61M5/1723 ,  A61M2005/14208 ,  A61M2205/3523 ,  A61M2230/00 ,  A61M2230/04 ,  A61M2230/63 ,  A61N1/3962

    摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).

    摘要翻译： 由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。 药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。 患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。 交感神经心血管药剂是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西林，美托洛尼，美托咪定和 右美托咪定）。

    Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure
    2.
    发明申请
    Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure 有权
    向中枢神经系统递送交感神经心血管药物以对抗心力衰竭和与心力衰竭相关的病理

    公开(公告)号：US20050177135A1

    公开(公告)日：2005-08-11

    申请号：US10773965

    申请日：2004-02-06

    申请人： Keith Hildebrand ,  Michael Ujhelyi ,  Xiaohong Zhou ,  Daniel Sigg ,  Linda Page

    发明人： Keith Hildebrand ,  Michael Ujhelyi ,  Xiaohong Zhou ,  Daniel Sigg ,  Linda Page

    IPC分类号： A61B5/02 ,  A61M5/142 ,  A61M5/168 ,  A61M5/172 ,  A61N1/39 ,  A61K9/22

    CPC分类号： A61M5/142 ,  A61M5/14276 ,  A61M5/1723 ,  A61M2005/14208 ,  A61M2205/3523 ,  A61M2230/00 ,  A61M2230/04 ,  A61M2230/63 ,  A61N1/3962

    摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.

    摘要翻译： 由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解症状，另外治疗与HF有关的心力衰竭（HF）和病理学。 药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。 患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与HF相关的生理学参数（或与HF相关的病理学）和触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。 交感神经心血管药剂是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂组成的组之一，例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫西康定，甲基多巴，甲苯噻嗪，胍法辛，美托咪定，美托咪定和 右美托咪定。

    Methods of treating cardiac disorders by suppressing the expression of the potassium inwardly-rectifying channel
    5.
    发明申请
    Methods of treating cardiac disorders by suppressing the expression of the potassium inwardly-rectifying channel 审中-公开
    通过抑制钾内向整流通道的表达来治疗心脏疾病的方法

    公开(公告)号：US20050244377A1

    公开(公告)日：2005-11-03

    申请号：US11022368

    申请日：2004-12-22

    申请人： Daniel Sigg ,  James Coles ,  Michael Ujhelyi ,  Rudy Padua ,  Daisy Cross ,  William Kaemmerer

    发明人： Daniel Sigg ,  James Coles ,  Michael Ujhelyi ,  Rudy Padua ,  Daisy Cross ,  William Kaemmerer

    IPC分类号： A61K48/00 ,  C12N15/113 ,  C12N15/86

    CPC分类号： C12N15/1138 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53

    摘要： The present invention is directed toward methods for regulating biological pacemaking activity and devices used in such regulation. Such regulation can be accomplished by introducing genetic material to the heart by transfecting heart cells of the atrium or ventricle with an oligonucleotide, small interfering RNA, that silence KCNJ2, and suppress the IK1 current. Suppression (or silencing) of KCNJ2 subsequently induces pacemaker-like activities in previously regular myocytes. This invention provides for methods of targeted delivery using a fluid delivery catheter. Such a catheter allows the targeting of a specific area in the atrium or the ventricle of the heart. Also, combination methods of treating arrhythmia with traditional device-based therapies (e.g., pacemakers and defibrillators) and an oligonucleotide of the subject invention.

    摘要翻译： 本发明涉及用于调节生物起搏活性的方法和用于这种调节的装置。 通过用心脏或心室的心脏细胞转染心脏的遗传物质可以通过用沉默KCNJ2的寡核苷酸，小干扰RNA，抑制Iκ1电流来引入遗传物质来实现这种调节。 KCNJ2的抑制（或沉默）随后在以前的正常心肌细胞中诱导起搏器样活性。 本发明提供了使用流体输送导管进行靶向递送的方法。 这样的导管允许靶向心房的心房或心室的特定区域。 此外，用传统的基于装置的疗法（例如起搏器和除颤器）治疗心律失常的组合方法和本发明的寡核苷酸。

    Methods and systems for providing therapies into the pericardial space
    6.
    发明申请
    Methods and systems for providing therapies into the pericardial space 审中-公开
    用于向心包空间提供疗法的方法和系统

    公开(公告)号：US20050154370A1

    公开(公告)日：2005-07-14

    申请号：US11000538

    申请日：2004-12-01

    申请人： Daniel Sigg ,  Michael Ujhelyi ,  Mary Morris

    发明人： Daniel Sigg ,  Michael Ujhelyi ,  Mary Morris

    IPC分类号： A61B17/00 ,  A61B17/22 ,  A61B17/34 ,  A61B18/14 ,  A61M31/00

    CPC分类号： A61M5/14276 ,  A61B17/00234 ,  A61B17/3417 ,  A61B17/3478 ,  A61B18/1492 ,  A61B2017/00247 ,  A61B2017/003 ,  A61B2017/22077 ,  A61B2017/3484 ,  A61B2017/3488 ,  A61B2017/349 ,  A61B2018/00291 ,  A61B2018/00357 ,  A61B2018/00392 ,  A61M5/1723 ,  A61M2005/1405 ,  A61M2205/3523

    摘要： Methods and systems for transvenously accessing the pericardial space via the vascular system and atrial wall, particularly through the superior vena cava and right atrial wall, to deliver a pharmacologic agent, particularly a NO-donor drug, to the heart are disclosed. A proximal connector of an infusion catheter is coupled to an infusion pump, and a distal catheter segment having a distal infusion catheter lumen end opening is disposed in the pericardial space. The implantable infusion pump is operable in conjunction with an implantable ischemia monitor to monitor the ischemic state and trigger delivery or regulate the periodic delivery of the pharmacologic agent to optimally treat ischemia. The patient may operate a patient activator that the patient when feeling ischemia symptoms to transmit a signal that is received by the implantable infusion pump and triggers delivery of a bolus and/or continuous infusion.

    摘要翻译： 公开了通过血管系统和心房壁，特别是通过上腔静脉和右心房壁经心脏进入心包空间的方法和系统，以向心脏递送药理学特别是NO供体药物。 输注导管的近端连接器联接到输注泵，并且具有远端输注导管腔端部开口的远侧导管段设置在心包空间中。 可植入输注泵可与可植入缺血监测器结合操作以监测缺血状态并触发递送或调节药理学剂的周期性递送以最佳地治疗缺血。 患者可以操作患者活化剂，当感觉到缺血症状时患者传递由可植入输液泵接收的信号并触发推注和/或连续输注的传递。

    Universal actuator particularly for dashboards
    7.
    发明申请
    Universal actuator particularly for dashboards 有权
    通用执行器特别适用于仪表盘

    公开(公告)号：US20070189025A1

    公开(公告)日：2007-08-16

    申请号：US10569084

    申请日：2004-08-27

    申请人： Daniel Sigg ,  Corinne Zuppiger-Lachat

    发明人： Daniel Sigg ,  Corinne Zuppiger-Lachat

    IPC分类号： B60Q1/124

    CPC分类号： G01D11/28

    摘要： An electric dashboard actuator including an electric motor driving an indicator. The electric motor includes a hollow output shaft of which the ends are located at and flush with two opposite surfaces of the motor, and the indicator includes a male coupling member with a cross-section matching the cross-section of the hollow motor output shaft. One motor surface includes a male or female coupling perpendicular to the surface.

    摘要翻译： 包括驱动指示器的电动马达的电气仪表板执行器。 电动机包括中空输出轴，其端部位于并与电动机的两个相对表面齐平，并且该指示器包括具有与中空电动机输出轴的横截面匹配的横截面的阳联接构件。 一个电动机表面包括垂直于表面的阳或阴耦合。

    Dashboard indicator module
    9.
    发明授权
    Dashboard indicator module 有权
    仪表板指示灯模块

    公开(公告)号：US08347807B2

    公开(公告)日：2013-01-08

    申请号：US12301706

    申请日：2007-05-23

    申请人： Daniel Sigg ,  Corinne Zuppigger-Lachat

    发明人： Daniel Sigg ,  Corinne Zuppigger-Lachat

    IPC分类号： G01D11/28

    CPC分类号： G01D11/28 ,  B60K2350/1064 ,  G01D13/265

    摘要： A dashboard indicator module including a rotating actuator including a hollow output shaft controlling movement of an indicator with a light conducting path, connected to a light source, diffusing a light at an angle, and a reduction gear set. The external diameter of the conducting path is between 2.6 and 5.5 millimeters.

    摘要翻译： 一种仪表板指示器模块，包括旋转致动器，其包括中空输出轴，其控制指示器与导光路径的移动，连接到光源，以一角度散射光和减速齿轮组。 导电路径的外径为2.6至5.5毫米。

    Rate control during AF using cellular intervention to modulate AV node
    10.
    发明申请
    Rate control during AF using cellular intervention to modulate AV node 有权
    使用细胞干预调整AV节点的AF期间的速率控制

    公开(公告)号：US20060247697A1

    公开(公告)日：2006-11-02

    申请号：US11116621

    申请日：2005-04-28

    申请人： Vinod Sharma ,  Daniel Sigg

    发明人： Vinod Sharma ,  Daniel Sigg

    IPC分类号： A61N1/362

    CPC分类号： A61N1/362 ,  A61K9/0019 ,  A61K31/221 ,  A61K38/177 ,  A61N1/0568

    摘要： A biologic intervention method and apparatus generates a persistent modification to an AV node that is physiologically stable after the agent has matured but is alterable with subsequent application of an agent. Specifically, the generic agent is used to modulate a node in a cardiac conduction system including rate control using one and a combination of a family of K+ channel or equivalent. Specifically, the channel is implemented to slow conduction by generating an outward current during optimization of action potential and repolarization phase thus decreasing the current that is available to excite downstream cells. A Kv 1.3 channel, for example, may be used as the biologic channel. The invention enables reversal of the modulation or adjustment for various heart rates (BPM) based on medical and patient-specific needs.

    摘要翻译： 生物干预方法和装置对于在该药剂已经成熟但随后随后施用药剂而可变化的生理稳定的AV节点产生持久性修饰。 具体地，通用试剂用于调制心脏传导系统中的节点，包括使用一个和一组K + SUPER通道或等同物的组合的速率控制。 具体地，通过在动作电位和复极相优化期间产生向外的电流来实现缓慢传导，从而减少可用于激发下游单元的电流。 例如，可以使用Kv1.3通道作为生物通道。 本发明能够根据医疗和患者特定的需要逆转各种心率（BPM）的调节或调整。